263 related articles for article (PubMed ID: 25057021)
1. Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma.
Chaturvedi A; Hoffman LM; Jensen CC; Lin YC; Grossmann AH; Randall RL; Lessnick SL; Welm AL; Beckerle MC
Mol Biol Cell; 2014 Sep; 25(18):2695-709. PubMed ID: 25057021
[TBL] [Abstract][Full Text] [Related]
2. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
Sankar S; Bell R; Stephens B; Zhuo R; Sharma S; Bearss DJ; Lessnick SL
Oncogene; 2013 Oct; 32(42):5089-100. PubMed ID: 23178492
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
4. EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.
Tanner JM; Bensard C; Wei P; Krah NM; Schell JC; Gardiner J; Schiffman J; Lessnick SL; Rutter J
Mol Cancer Res; 2017 Nov; 15(11):1517-1530. PubMed ID: 28720588
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
[TBL] [Abstract][Full Text] [Related]
6. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
[TBL] [Abstract][Full Text] [Related]
7. A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma.
Sankar S; Tanner JM; Bell R; Chaturvedi A; Randall RL; Beckerle MC; Lessnick SL
Mol Cell Biol; 2013 Nov; 33(22):4448-60. PubMed ID: 24043308
[TBL] [Abstract][Full Text] [Related]
8. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
9. RUNX3 facilitates growth of Ewing sarcoma cells.
Bledsoe KL; McGee-Lawrence ME; Camilleri ET; Wang X; Riester SM; van Wijnen AJ; Oliveira AM; Westendorf JJ
J Cell Physiol; 2014 Dec; 229(12):2049-56. PubMed ID: 24812032
[TBL] [Abstract][Full Text] [Related]
10. EWS/FLI mediated reprogramming of 3D chromatin promotes an altered transcriptional state in Ewing sarcoma.
Showpnil IA; Selich-Anderson J; Taslim C; Boone MA; Crow JC; Theisen ER; Lessnick SL
Nucleic Acids Res; 2022 Sep; 50(17):9814-9837. PubMed ID: 36124657
[TBL] [Abstract][Full Text] [Related]
11. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O
Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530
[TBL] [Abstract][Full Text] [Related]
12. EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology.
Zhou Z; Yu L; Kleinerman ES
Cancer; 2014 Feb; 120(4):579-88. PubMed ID: 24415532
[TBL] [Abstract][Full Text] [Related]
13. Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription.
Patel M; Simon JM; Iglesia MD; Wu SB; McFadden AW; Lieb JD; Davis IJ
Genome Res; 2012 Feb; 22(2):259-70. PubMed ID: 22086061
[TBL] [Abstract][Full Text] [Related]
14. TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma.
Seong BKA; Dharia NV; Lin S; Donovan KA; Chong S; Robichaud A; Conway A; Hamze A; Ross L; Alexe G; Adane B; Nabet B; Ferguson FM; Stolte B; Wang EJ; Sun J; Darzacq X; Piccioni F; Gray NS; Fischer ES; Stegmaier K
Cancer Cell; 2021 Sep; 39(9):1262-1278.e7. PubMed ID: 34329586
[TBL] [Abstract][Full Text] [Related]
15. Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development.
De Vito C; Riggi N; Suvà ML; Janiszewska M; Horlbeck J; Baumer K; Provero P; Stamenkovic I
PLoS One; 2011; 6(8):e23592. PubMed ID: 21853155
[TBL] [Abstract][Full Text] [Related]
16. Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis.
Showpnil IA; Miller KR; Taslim C; Pishas KI; Lessnick SL; Theisen ER
J Vis Exp; 2020 Jun; (160):. PubMed ID: 32658189
[TBL] [Abstract][Full Text] [Related]
17. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
[TBL] [Abstract][Full Text] [Related]
18. Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity.
Balestra T; Manara MC; Laginestra MA; Pasello M; De Feo A; Bassi C; Guerzoni C; Landuzzi L; Lollini PL; Donati DM; Negrini M; Magnani M; Scotlandi K
Mol Cancer Ther; 2022 Jan; 21(1):58-69. PubMed ID: 34667115
[TBL] [Abstract][Full Text] [Related]
19. EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Issaq SH; Mendoza A; Kidner R; Rosales TI; Duveau DY; Heske CM; Rohde JM; Boxer MB; Thomas CJ; DeBerardinis RJ; Helman LJ
Mol Cancer Ther; 2020 Jul; 19(7):1520-1529. PubMed ID: 32371575
[TBL] [Abstract][Full Text] [Related]
20. CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.
Sun H; Lin DC; Cao Q; Guo X; Marijon H; Zhao Z; Gery S; Xu L; Yang H; Pang B; Lee VK; Lim HJ; Doan N; Said JW; Chu P; Mayakonda A; Thomas T; Forscher C; Baloglu E; Shacham S; Rajalingam R; Koeffler HP
Cancer Res; 2016 May; 76(9):2687-97. PubMed ID: 26956669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
